[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100562742":3},{"organization":4,"armGroups":7,"interventions":7,"overallOfficials":8,"centralContacts":13,"locations":22,"responsibleParty":37,"collaborators":7,"id":40,"slug":7,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":7,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":7,"enrollmentInfo":48,"targetDuration":7,"studyType":51,"phases":7,"briefSummary":52,"conditions":53,"keywords":55,"overallStatus":24,"whyStopped":7,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":71},{"fullName":5,"class":6},"Zhongda Hospital","OTHER",null,[9],{"name":10,"affiliation":11,"role":12},"Gao- Teng, M.D","Zhongda hospital, Southeast university, Nanjing, China","PRINCIPAL_INVESTIGATOR",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},"Gao-Jun Teng, M.D","CONTACT","+86-02583272121","gjteng@vip.sina.com",{"name":20,"role":16,"phone":17,"phoneExt":7,"email":21},"Hai-Dong Zhu, M.D","zhuhaidong9509@163.com",[23],{"facility":5,"status":24,"city":25,"state":26,"zip":7,"country":27,"countryCode":28,"cosmosGeoPoint":29,"geoPoint":34,"contacts":35},"RECRUITING","Nanjing","Jiangsu","China","CN",{"type":30,"coordinates":31},"Point",[32,33],118.77778,32.06167,{"lat":33,"lon":32},[36],{"name":15,"role":16,"phone":17,"phoneExt":7,"email":18},{"type":12,"investigatorFullName":38,"investigatorTitle":39,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Gao-jun Teng","President","100562742",false,"NCT06607120","Prognosis Stratification for Advanced HCC Receiving TACE with PD-1\u002FPD-L1 Inhibitors and Molecular Target Therapies","Personalized Model of Prognosis Stratification for Patients with Advanced HCC Receiving TACE Combined with PD-1\u002FPD-L1 Inhibitors Plus Molecular Target Therapies","Inclusion Criteria:\n\n1. Has a diagnosis of HCC confirmed by radiology, histology, or cytology;\n2. Barcelona Clinic Liver Cancer (BCLC) stage C with the presence of extrahepatic spread and\u002For macrovascular invasion;\n3. Has not received any previous systemic therapy for HCC (including chemotherapy, molecularly targeted therapy, immunotherapy);\n4. Both PD-1\u002FPD-L1 inhibitors and anti-angiogenesis drugs patients received only include marketed drugs but are not limited to HCC approval;\n5. TACE was performed after the first PD-1\u002FPD-L1 inhibitor\u002Fanti-angiogenic drug treatment or before treatment (within 3 months);\n6. Received at least 1 cycle of PD-1\u002FPD-L1 inhibitor\u002Fanti-angiogenic drug combination therapy after TACE treatment;\n7. Has repeated measurable intrahepatic lesions;\n\nExclusion Criteria:\n\n1. Cholangiocarcinoma, fibrolamellar, sarcomatoid hepatocellular carcinoma, and mixed hepatocellular\u002Fcholangiocarcinoma subtypes(confirmed by histology, or pathology) are not eligible;\n2. Unable to meet criteria of combination timeframe described above;\n3. Child-Pugh C or PS\\>2 or Severe hepatic encephalopathy","ALL","18 Years",{"count":49,"type":50},950,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to establish a personalized model of prognosis stratification for patients with advanced-stage hepatocellular carcinoma (HCC) receiving transarterial chemoembolization (TACE) in combination with immune checkpoint inhibitors (ICIs) and molecular target therapies.",[54],"Hepatocellular Carcinoma",[56,57,58,59,60,61],"hepatocellular carcinoma","transarterial chemoembolization","immune checkpoint inhibitors","molecular target therapies","advanced stage","prognosis model","2024-09-20",{"date":64,"type":65},"2024-09-23","ACTUAL",{"date":67,"type":65},"2024-06-01",{"date":69,"type":50},"2025-03-01",{"name":5,"class":6},1]